1-17 of 17
Xiaojia Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract OT2-27-02: A prospective phase II study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally advanced or metastatic breast cancer

Xiaojia Wang, Jian Huang
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): OT2-27-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-OT2-27-02
Published: 15 February 2022
View article
Journal Articles

Abstract P1-16-02: A randomized phase II study investigating oral metronomic vinorelbine versus conventional dosage of vinorelbine in HER2-negative metastatic breast cancer previously treated with anthracycline or taxane:clinical results and biomarker analysis

Fei Ma, Xinlan Liu, Yanxia Shi, Xiuwen Guan, Huihui Li, Xiaojia Wang, Yuee Teng, Qiang Liu, Jin Yang, Man Li, Qingyuan Zhang, Weihong Zhao, Caiwen Du, Lili Sheng, Binghe Xu
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-16-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P1-16-02
Published: 15 February 2022
View article
Journal Articles

Abstract P2-08-22: Correlation of ER (ESR1), PR (PGR), and HER2 (ERBB2) at protein and mRNA levels in operable breast cancer

Lei Lei, Xiaojia Wang, Skye Hung-Chun Cheng
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-08-22.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P2-08-22
Published: 15 February 2022
View article
Journal Articles

Abstract P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer: Results from a phase I study

Jian Zhang, Dongmei Ji, Li Cai, Herui Yao, Min Yan, Xiaojia Wang, Weina Shen, Yiqun Du, Hui Pang, Xiuping Lai, Huiai Zeng, Jian Huang, Yan Sun, Xinxin Peng, Junfang Xu, Jing Yang, Fei Yang, Ting Xu, Xichun Hu
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-10.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P2-13-10
Published: 15 February 2022
View article
Journal Articles

Abstract P2-13-31: Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial

Xiaojia Wang, Jian Huang, Yabing Zheng, Xiying Shao, Wenming Cao, Zhanhong Chen, Yanxia Shi, Li Cai, Wenyan Chen, Zhen Guo, Jian Liu, Peng Shen, Yiding Chen, Xian Wang, Huiping Li, Man Li
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-31.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P2-13-31
Published: 15 February 2022
View article
Journal Articles

Abstract P2-13-40: Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study

Yiqun Li, Zhongsheng Tong, Quchang Ouyang, Xinhong Wu, Wei Li, Li Cai, Zhiyong Yu, Zhengxiang Han, Xiaojia Wang, Man Li, Jin Yang, Li Li, Zhaofeng Niu, Haibo Wang, Qitang Wang, Yi Li, Yuee Teng, Shiguang Zhu, Binghe Xu
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P2-13-40.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-P2-13-40
Published: 15 February 2022
View article
Journal Articles

Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer

Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wei Li, Quchang Ouyang, Jingfen Wang, Zhongsheng Tong, Min Yan, Huiping Li, Xiaohua Zeng, Changping Shan, Xian Wang, Xi Yan, Jian Zhang, Yue Zhang, Jiani Wang, Liang Zhang, Ying Lin, Jifeng Feng, Qianjun Chen, Jian Huang, Yongkui Lu, Hongsheng Li, Jinsheng Wu, Jing Cheng, Yanrong Hao, Cuizhi Geng, Min Lu, Yanping Li, Xi Chen, Lihua Song, Xueying Wu, Changlu Hu, Xinhong Wu, Xiaojia Wang, Yueyin Pan, Yuehong Cui, Guohua Yu, Sanyuan Sun
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS1-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS1-06
Published: 15 February 2022
View article
Journal Articles

Abstract PD8-05: Overall survival (OS) results from the phase III PHENIX trial of HER2+ metastatic breast cancer treated with pyrotinib plus capecitabine

Zefei Jiang, Min Yan, Li Bian, Tao Wang, Xichun Hu, Qingyuan Zhang, Quchang Ouyang, Jifeng Feng, Yongmei Yin, Tao Sun, Zhongsheng Tong, Xiaojia Wang, Herui Yao, Shuping Jiang, Xiaoyu Zhu, Jianjun Zou
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD8-05.
DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD8-05
Published: 15 February 2022
View article
Journal Articles

Abstract CT117: Phase I dose-escalation and dose-expansion trial of CDK4/6 inhibitor FCN-437c in Chinese female patients with ER+HER2- advanced breast cancer (ABC)

Jian Zhang, Xiaojia Wang, Xian Wang, Aimin Hui, Zhuli Wu, Ling Tian, Changjiang Xu, Yuchen Yang, Wenjing Zhang, Xichun Hu
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT117.
DOI: https://doi.org/10.1158/1538-7445.AM2021-CT117
Published: 01 July 2021
View article
Journal Articles

Abstract PS13-25: Management of abemaciclib associated diarrhea in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Analysis of the MONARCH plus study

Zefei Jiang, Xichun Hu, Qingyuan Zhang, Tao Sun, Yongmei Yin, Huiping Li, Min Yan, Zhongsheng Tong, Christina Pimentel Oppermann, Yunpeng Liu, Romulo Costa, Man Li, Xi Chen, Ying Cheng, Quchang Ouyang, Ning Liao, Xiaojia Wang, Xinhong Wu, Jifeng Feng, Roberto Hegg, Govindbabu Kanaka Setty, Amit Agarwal, Jyoti Bajpai, Jing Cheng, Gustavo Girotto, Chanchal Goswami, Wenjing Hu, Jian Huang, MA Coccia Portugal, Jin Yang, Rongsheng Zheng, Fabio Andre Franke, Qiang Liu, Yunjiang Liu, Yongkui Lu, Cristiano Souza, Shiying Yu, Nalini Kilara, Harsha Panchal, Ashish Singh, Shona Nag, Jian Liu, Bernardo Rapoport, Neonyana Keorapetse Rebecca Tabane, Hongxia Wang, Ning Wang, Rubing Han, Wanli Zhang
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS13-25.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS13-25
Published: 15 February 2021
View article
Journal Articles

Abstract PS13-01: Primary analysis of OVERSTEP: A multicenter, randomized clinical trial of capecitabine or endocrine therapy as a maintenance therapy after the 1st-line chemotherapy in hormone receptor positive and HER2-negative advanced/metastatic breast cancer

Jian Huang, Xiying Shao, Li Cai, Yanxia Shi, Zhanhong Chen, Ping Huang, Yongmei Yin, Lili Zhang, Peng Shen, Wenming Cao, Weiwu Ye, Yuan Huang, Caijin Lou, Lei Lei, Yabin Zheng, Weibin Zou, Junqing Chen, Xiaojia Wang
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS13-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS13-01
Published: 15 February 2021
View article
Journal Articles

Abstract PD7-08: Everolimus in first-line treatment of advanced premenopausal breast cancer: Results from MIRACLE (everoliMus trIal foR AdvanCed premenopausaL brEast cancer) study

Ying Fan, Tao Sun, Zhimin Shao, Qingyuan Zhang, Quchang Ouyang, Zhongsheng Tong, Shusen Wang, Yang Luo, Yuee Teng, Xiaojia Wang, Shu Wang, Qiang Liu, Jifeng Feng, Kunwei Shen, Yanqiu Song, Jiayu Wang, Fei Ma, Qing Li, Pin Zhang, Binghe Xu
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD7-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS19-PD7-08
Published: 15 February 2020
View article
Journal Articles

Abstract P5-09-02: The CYP19 RS4646 polymorphism is related to the prognosis of stage I–II and operable stage III breast cancers

Xiying Shao, Xiaojia Wang, Yangbing Zheng, Ping Huang, Jian Huang
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-09-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS14-P5-09-02
Published: 01 May 2015
View article
Journal Articles

Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)

Joseph Gligorov, Jose Bines, Emilio Alba, Giorgio Mustacchi, Saverio Cinieri, Vineet Gupta, Jean-Yves Pierga, Hakan Bozcuk, Rabab Gaafar, Sudeep Gupta, Guillermo Lopez Vivanco, Xiaojia Wang, Romulo Costa, Kadri Altundag, Ewa Chmielowska, Sabine de Ducla, Ulrich Freudensprung, Paulo Cortes, Dinesh Doval
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P2-17-01.
DOI: https://doi.org/10.1158/1538-7445.SABCS14-P2-17-01
Published: 01 May 2015
View article
Journal Articles

Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can

Dinesh Doval, Saverio Cinieri, Hakan Bozcuk, Jean-Yves Pierga, Kadri Altundag, Xiaojia Wang, Sudeep Gupta, Guillermo Lopez Vivanco, Vineet Gupta, Ewa Chmielowska, Jose Bines, Philippe Montcuquet, Alfred Namour, Emilio Alba, Giorgio Mustacchi, Paulo Cortes, Sabine de Ducla, Ulrich Freudensprung, Lesley Fallowfield, Joseph Gligorov
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P2-12-16.
DOI: https://doi.org/10.1158/1538-7445.SABCS14-P2-12-16
Published: 01 May 2015
View article
Journal Articles

Abstract P3-10-02: Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer

Xichun Hu, Binghe Xu, Li Cai, Zhonghua Wang, Biyun Wang, Jian Zhang, Yuee Teng, Zhongsheng Tong, Yueyin Pan, Yongmei Yin, Changping Wu, Zefei Jiang, Xiaojia Wang, Guyin Lou, Donggeng Liu, Jifeng Feng, Jianfeng Luo, Jiong Wu, Zhimin Shao, Joseph Ragaz
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P3-10-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS14-P3-10-02
Published: 01 May 2015
View article
Journal Articles

Abstract P1-13-07: A phase III study of fulvestrant 500 mg versus 250 mg in postmenopausal Chinese women with advanced breast cancer and disease progression following failure on prior antiestrogen or aromatase inhibitor therapy: Supporting superior clinical benefit for the

Zefei Jiang, Qingyuan Zhang, Zhimin Shao, Kunwei Shen, Li Li, Jifeng Feng, Zhongseng Tong, Kangsheng Gu, Xiaojia Wang, Binghe Xu, Guofang Sun, Huifang Chen, Yuri Rukazenkov
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P1-13-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS14-P1-13-07
Published: 01 May 2015
View article